Prospective 2 year study of accelerated pulsed transepithelial corneal collagen cross-linking outcomes for keratoconus

Session Details

Session Title: Cross-Linking Protocols

Session Date/Time: Monday 24/09/2018 | 14:00-16:00

Paper Time: 15:20

Venue: Room A3, Podium 3

First Author: : M.Ziaei NEW ZEALAND

Co Author(s): :    H. Vellara   A. Gokul   J. Meyer   D. Patel   C. McGhee        

Abstract Details

Purpose:

To report 2-year outcomes of trans-epithelial, accelerated, pulsed, corneal collagen crosslinking (t-ACXL) for patients with progressive keratoconus.

Setting:

University hospital tertiary referral center.

Methods:

Prospective, interventional case series. Forty eyes with progressive keratoconus undergoing t-ACXL were included. Treatment was performed with pulsed illumination (1 sec. on/1 sec. off) using 45 mW/cm2 for 5 minutes and 20 seconds, for a surface dose of 7.2 Jcm2. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction spherical equivalent (MRSE), corneal tomography, anterior segment optical coherence tomography (OCT), densitometry, specular microscopy and CorVis ST derived biomechanical properties of the cornea were evaluated pre-operatively and at 12 and 24 months post-operatively.

Results:

The mean patient age was 23.32 years ± 5.18 years (SD). The mean CDVA significantly improved from 0.38 ± 0.32 logMAR at baseline to 0.30 ± 0.21 logMAR at 24 months (P=0.04). The highest concavity time was significantly reduced from 17.21±0.57 ms at baseline to 16.93±0.52 ms at 24 months (P=0.02) and the peak distance increased significantly from 5.06±0.25 mm at baseline to 5.17±0.21mm at 24 months (P<0.01). There was no significant difference in UDVA, MRSE, asymmetry indices, tomographic parameters, densitometry and endothelial density. The improvement in visual acuity was inversely correlated with preoperative CDVA and preoperative KMAX.

Conclusions:

In this prospective study T-ACXL appeared safe and effective in halting progression of keratoconus within a follow-up period of 24 months.

Financial Disclosure:

-